At present, the GLP-1 receptor agonists that have been marketed in China mainly include exenatide, liraglutide, exenatide long-acting preparation, dulaglutide, lisinatide, benaglutide, and pegylated losenatide. According to the length of action, it can be divided into short-acting and long-acting GLP-1 receptor agonists. Short-acting GLP-1 receptor agonists are injected subcutaneously multiple times a day, while long-acting GLP-1 agonists can be injected subcutaneously once daily or once a week. GLP-1 receptor agonists stimulate insulin secretion when glucose concentrations in the body are elevated. When glucose concentrations decrease and tend to normalize, insulin secretion decreases. Thus, GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner. At the same time, GLP-1 receptor agonists reduce glucagon secretion in a glucose-dependent manner. In addition, GLP-1 receptor agonists exert hypoglycemic effects by various mechanisms such as slowing gastric emptying, central appetite suppression, and reducing food intake.